Adagio Medical to Present at BTIG MedTech Conference Amid Key Trial Progress
Event summary
- Adagio Medical will present at the BTIG 13th Annual MedTech Conference on February 10, 2026.
- The company's vCLAS™ Cryoablation System is under evaluation in the FULCRUM-VT U.S. Pivotal IDE Trial.
- FULCRUM-VT has fully enrolled 209 patients with structural heart disease.
- The system is CE Marked and commercially available in Europe but limited to investigational use in the U.S.
The big picture
Adagio Medical's participation in the BTIG conference comes at a critical juncture as it awaits the outcomes of its FULCRUM-VT trial, which could pave the way for FDA approval and broader market access. The company's focus on ventricular arrhythmias with its proprietary ULTA technology positions it in a niche but growing segment of the cardiac ablation market. Success in this space could significantly enhance its competitive standing against established players.
What we're watching
- Regulatory Pathway
- Whether the FULCRUM-VT trial results will support FDA premarket approval for the vCLAS™ system.
- Commercial Expansion
- The pace at which Adagio can expand the vCLAS™ system's commercial availability beyond Europe.
- Market Positioning
- How Adagio's Ultra-Low Temperature Cardiac technology will differentiate it in the competitive cardiac ablation market.